OBSERVATIONAL STUDIES

Characterization of exposure and epidemiology in a flavivirus-endemic setting." Here, we developed statistical models to analyze age-stratified flavivirus seroprevalence data in a context where multiple flaviviruses co-circulate. These results allowed us to characterize the force of infection, attack rate, and transmissibility of Zika. 2016.

The results of this study made it possible to define DENV target cells and the immunological hallmarks of severe dengue (SD) progression by integrating single-cell RNA-Seq 2 (viscRNA-Seq 2) with functional assays. These findings revealed the existence of DENV target cells that provide insight into SD pathogenesis beyond antibody-dependent enhancement. 2019–2020.

The objective is to strengthen surveillance and response capacity regarding outbreaks of emerging and re-emerging arboviral infections, emphasizing early diagnosis and the optimization of resources used by healthcare providers to reduce morbidity and mortality. 2019–Present..

This study found that acute-phase inflammation levels have an additional impact—beyond clinical severity—on quality of life during the convalescent phase regarding mood, whereas increased age and NS1 antigenemia levels are associated with the development of fatigue in the late convalescent phase, independently of clinical severity. This study contributes to characterizing the convalescent phase of dengue in a sample predominantly composed of minors, thereby addressing a significant aspect of the underestimated burden of dengue among children and adolescents during an epidemic—an under-researched area. 2022.

A study employing a simple, pragmatic, multidisciplinary approach to examine the key factors influencing the spread of arboviruses—DENV, CHIKV, ZIKV, and YFV—across three distinct regions of Colombia. By analyzing aspects of clinical practice, the virus, the mosquito vector, and population immunity, the study generates practical, easily implementable recommendations for decision-makers. 2019–2023.

Objective: to estimate the prevalence of rheumatic disease and chronic inflammatory arthropathy following chikungunya, compare antibody levels in individuals with rheumatic disease seven years after chikungunya exposure, and characterize the impact on their quality of life. 2022–Present.

The study's primary objective is to identify clinical and immunological variables indicative of a protective and sustained response to COVID-19 vaccines, thereby enabling risk stratification and generating knowledge relevant to the design of vaccination strategies. 2022–Present.

In collaboration with researchers from the Universidad Industrial de Santander, observational forecasting and diagnostic studies—as well as the AEDES Program—were conducted between 2003 and 2018. Addressing needs identified for the Integrated Management Strategy (EGI), this program was designed by the AEDES Network to generate and transfer knowledge contributing to a sustainable, evidence-based dengue intervention model, within the framework of national and international guidelines aimed at reducing the disease burden. The AEDES cooperation and knowledge-generation network is a collaborative alliance that conducts multicenter studies. The AEDES Network coordinates the efforts of research groups affiliated with domestic and foreign universities, research and technological development centers, and government entities.

CLINICAL TRIALS

  • -Efficacy and safety of a new tetravalent dengue vaccine in healthy children and adolescents aged 9 to 16 years in Latin America. ClinicalTrials.gov ID: NCT01374516. 2011–2018.
  • -Study of a booster dose of a tetravalent dengue vaccine in subjects who previously completed the 3-dose regimen. ClinicalTrials.gov ID: NCT02623725. 2016–2019.
  • -Efficacy, immunogenicity, and safety of a *Clostridium difficile* toxoid vaccine in subjects at risk of developing *C. difficile* infection. ClinicalTrials.gov ID: NCT01887912. 2013–2018.
  • -Randomized Phase 2/2B study to evaluate the safety, immunogenicity, and efficacy of a Zika virus DNA vaccine in healthy adults and adolescents. ClinicalTrials.gov ID: NCT03110770. 2018.
  • -Controlled trial to evaluate the safety and immunogenicity of a chikungunya vaccine in Latin America and Asia (IVICHIK001). ClinicalTrials.gov ID: NCT04566484. 2022–Present.
  • - JNJ-64281802 for the prevention of dengue infection. ClinicalTrials.gov ID: NCT05201794. 2023–Present.

Síguenos en Instagram @ipscdi